Upgrade to SI Premium - Free Trial

Form 3 Sensei Biotherapeutics, For: Jun 12 Filed by: Ramasastry Saira

June 16, 2026 4:23 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Ramasastry Saira
(Last) (First) (Middle)
C/O FAETH THERAPEUTICS, INC.
701 TILLERY STREET #12 #1010
(Street)
AUSTIN TX 78702
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/12/2026 		3. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ FTH ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) (1) 01/24/2036 Common Stock 8,718 (2) (3) 1.16 D
Employee Stock Option (right to buy) (4) 05/10/2034 Common Stock 5,929 (3) (5) 5.22 D
Explanation of Responses:
1. Beginning August 1, 2022, the shares subject to the option vest in a series of twenty-four (24) successive equal monthly installments.
2. Received in exchange for or a stock option to acquire an aggregate 43,739 shares of Faeth Holdings Therapeutics, Inc. ("HoldCo") common stock with an exercise price of $0.23 per share pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").
3. Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger").
4. Fully vested.
5. Received in exchange for a stock option to acquire an aggregate 29,746 shares of Faeth common stock with an exercise price of $1.04 per share pursuant to the Merger Agreement.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Josiah Craver, Attorney-in-Fact 06/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ATTACHMENTS / EXHIBITS

ex24-06162026_080621.htm

Categories

SEC Filings